Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1979 Jul;64(1):302–311. doi: 10.1172/JCI109452

Suppression of acute and chronic inflammation in tumor-bearing rats.

J P Brozna, P A Ward
PMCID: PMC372118  PMID: 156198

Abstract

Both acute and chronic cellular inflammatory reactions were suppressed in rats bearing malignant tumors. Inhibition of the acute inflammatory reactions was demonstrated in immune complex-induced vasculitis and in the accumulation of leukocytes in subcutaneously implanted polyvinyl sponges. Suppression of chronic inflammatory reactions was demonstrated in delayed type hypersensitivity skin reactions. In spite of these suppressed reactions, dermal reactivity to vasopermeability mediators was not diminished. Neither serum complement levels nor numbers of circulating leukocytes were depressed in animals with tumors. Suppression of inflammatory reactions was paralleled by a leukotactic defect which involved both neutrophils and monocytes. This defect could be ascribed to an abnormality in the serum that rendered both cell types leukotactically defective.

Full text

PDF
302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERG J. W. Inflammation and prognosis in breast cancer; a search for host resistance. Cancer. 1959 Jul-Aug;12(4):714–720. doi: 10.1002/1097-0142(195907/08)12:4<714::aid-cncr2820120414>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  2. Brozna J. P., Ward P. A. Antileukotactic properties of tumor cells. J Clin Invest. 1975 Sep;56(3):616–623. doi: 10.1172/JCI108131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Churchill W. H., Jr, Piessens W. F., Sulis C. A., David J. R. Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol. 1975 Sep;115(3):781–786. [PMC free article] [PubMed] [Google Scholar]
  4. Dvorak A. M., Connell A. B., Proppe K., Dvorak H. F. Immunologic rejection of mammary adenocarcinoma (TA3-St) in C57BL/6 mice: participation of neutrophils and activated macrophages with fibrin formation. J Immunol. 1978 Apr;120(4):1240–1248. [PubMed] [Google Scholar]
  5. Eilber F. R., Morton D. L. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970 Feb;25(2):362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  6. Eilber F. R., Morton D. L. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970 Feb;25(2):362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  7. Evans R., Alexander P. Cooperation of immune lymphoid cells with macrophages in tumour immunity. Nature. 1970 Nov 14;228(5272):620–622. doi: 10.1038/228620a0. [DOI] [PubMed] [Google Scholar]
  8. FLAX M. H., WAKSMAN B. H. Delayed cutaneous reactions in the rat. J Immunol. 1962 Oct;89:496–504. [PubMed] [Google Scholar]
  9. Fauve R. M., Hevin B., Jacob H., Gaillard J. A., Jacob F. Antiinflammatory effects of murine malignant cells. Proc Natl Acad Sci U S A. 1974 Oct;71(10):4052–4056. doi: 10.1073/pnas.71.10.4052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. HELMKAMP R. W., GOODLAND R. L., BALE W. F., SPAR I. L., MUTSCHLER L. E. High specific activity iodination of gamma-globulin with iodine-131 monochloride. Cancer Res. 1960 Nov;20:1495–1500. [PubMed] [Google Scholar]
  11. Johnson K. J., Anderson T. P., Ward P. A. Suppression of immune complex-induced inflammation by the chemotactic factor inactivator. J Clin Invest. 1977 May;59(5):951–958. doi: 10.1172/JCI108717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Johnson M. W., Maibach H. I., Salmon S. E. Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response? N Engl J Med. 1971 Jun 3;284(22):1255–1257. doi: 10.1056/NEJM197106032842210. [DOI] [PubMed] [Google Scholar]
  13. LAMB D., PILNEY F., KELLY W. D., GOOD R. A. A comparative study of the incidence of anergy in patients with carcinoma, leukemia, hodgkin's disease and other lymphomas. J Immunol. 1962 Oct;89:555–558. [PubMed] [Google Scholar]
  14. MAHONEY M. J., LEIGHTON J. The inflammatory response to a foreign body within transplantable tumors. Cancer Res. 1962 Apr;22:334–338. [PubMed] [Google Scholar]
  15. Maderazo E. G., Anton T. F., Ward P. A. Serum-associated inhibition of leukotaxis in humans with cancer. Clin Immunol Immunopathol. 1978 Feb;9(2):166–176. doi: 10.1016/0090-1229(78)90068-5. [DOI] [PubMed] [Google Scholar]
  16. Müftüoğlu A. U., Balkuv S. Passive transfer of tuberculin sensitivity to patients with Hodgkin's disease. N Engl J Med. 1967 Jul 20;277(3):126–129. doi: 10.1056/NEJM196707202770304. [DOI] [PubMed] [Google Scholar]
  17. Pike M. C., Snyderman R. Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. J Immunol. 1976 Oct;117(4):1243–1249. [PubMed] [Google Scholar]
  18. WARD P. A., COCHRANE C. G. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med. 1965 Feb 1;121:215–234. doi: 10.1084/jem.121.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
  20. Ward P. A., Lepow I. H., Newman L. J. Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol. 1968 Apr;52(4):725–736. [PMC free article] [PubMed] [Google Scholar]
  21. Wiener S., Lendvai S., Rogers B., Urivetzky M., Meilman E. Nonimmune chemotaxis in vivo: inhibition by complement depletion with cobra factor. Am J Pathol. 1973 Dec;73(3):807–816. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES